Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Conditions
- Estrogen Receptor Positive
- Progesterone Receptor Positive
- Recurrent Breast Carcinoma
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer
Interventions
- DRUG: Alisertib
- DRUG: Fulvestrant
- OTHER: Laboratory Biomarker Analysis
Sponsor
Mayo Clinic
Collaborators